- Home
- VRPX vs LIXT Comparison
VRPX vs LIXT Comparison
Compare VRPX & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRPX
- LIXT
- Stock Information
- Founded
- VRPX 2016
- LIXT 2005
- Country
- VRPX United States
- LIXT United States
- Employees
- VRPX N/A
- LIXT N/A
- Industry
- VRPX Medicinal Chemicals and Botanical Products
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- VRPX Health Care
- LIXT Health Care
- Exchange
- VRPX Nasdaq
- LIXT Nasdaq
- Market Cap
- VRPX 3.6M
- LIXT 4.1M
- IPO Year
- VRPX 2021
- LIXT N/A
- Fundamental
- Price
- VRPX $0.49
- LIXT $1.19
- Analyst Decision
- VRPX Hold
- LIXT
- Analyst Count
- VRPX 1
- LIXT 0
- Target Price
- VRPX N/A
- LIXT N/A
- AVG Volume (30 Days)
- VRPX 444.2K
- LIXT 31.7K
- Earning Date
- VRPX 05-12-2025
- LIXT 03-24-2025
- Dividend Yield
- VRPX N/A
- LIXT N/A
- EPS Growth
- VRPX N/A
- LIXT N/A
- EPS
- VRPX N/A
- LIXT N/A
- Revenue
- VRPX N/A
- LIXT N/A
- Revenue This Year
- VRPX N/A
- LIXT N/A
- Revenue Next Year
- VRPX N/A
- LIXT N/A
- P/E Ratio
- VRPX N/A
- LIXT N/A
- Revenue Growth
- VRPX N/A
- LIXT N/A
- 52 Week Low
- VRPX $1.08
- LIXT $1.02
- 52 Week High
- VRPX $105.98
- LIXT $3.80
- Technical
- Relative Strength Index (RSI)
- VRPX 15.43
- LIXT 41.29
- Support Level
- VRPX $1.08
- LIXT $1.18
- Resistance Level
- VRPX $1.78
- LIXT $1.31
- Average True Range (ATR)
- VRPX 0.39
- LIXT 0.10
- MACD
- VRPX -0.02
- LIXT 0.03
- Stochastic Oscillator
- VRPX 1.63
- LIXT 43.24
About VRPX Virpax Pharmaceuticals Inc.
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.